Tezspire market seen growing on severe asthma demand

The Business Research Company says the Tezspire market is expanding as severe asthma cases rise and biologic respiratory treatments gain wider use. The report also points to more clinical trials, stronger research spending and North America’s continued lead in the segment.

Why it matters: - Rising severe asthma rates are keeping demand high for targeted respiratory treatments. - Tezspire sits in a growing biologics category that is drawing more research, clinic adoption and investment. - The market outlook matters for drugmakers, clinicians and payers tracking shifts toward precision treatment in respiratory care.

What happened: - The Business Research Company published a Tezspire market report dated Nov. 12, 2026, covering market size, trends and forecasts through 2035. - The report says Tezspire is gaining traction as respiratory medicine and targeted biologic treatments advance. - The report says the market is being shaped by the increasing prevalence of severe asthma and improved medical research. - The report includes a free sample here: Download a free sample of the Tezspire market report. - The full report is available here: View the full Tezspire market report.

The details: - Tezspire is a biologic that blocks thymic stromal lymphopoietin, or TSLP, a protein that triggers inflammation in respiratory conditions. - The treatment is primarily prescribed for severe asthma and chronic obstructive pulmonary disease, or COPD. - The report says Tezspire helps reduce inflammation and improve respiratory function in patients whose symptoms are not adequately controlled by conventional treatments. - Market growth has been driven by more severe asthma cases, progress in monoclonal antibody technologies and wider adoption of biologics in respiratory healthcare. - The report also cites the growth of specialty respiratory clinics and better diagnostic techniques for asthma phenotypes as supporting factors. - Looking ahead, the market is expected to benefit from broader biologic treatment applications, higher demand for personalized respiratory therapies, more investment in immunology drug research and greater emphasis on early intervention protocols. - Forecast trends include wider use of targeted biologic therapies, more TSLP inhibitors in respiratory care, a stronger focus on managing severe asthma, expansion of biologic pipelines and more precision immunology. - The report says North America will remain the largest regional market for Tezspire in 2025. - Other regions covered include Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa. - North America’s lead is linked to high severe asthma prevalence, established healthcare infrastructure and strong investment in biologic drug development and clinical research.

Between the lines: - The report frames Tezspire as part of a broader shift from symptom management to mechanism-based treatment in respiratory disease. - The emphasis on clinical trials and personalized medicine suggests the market’s growth depends not just on disease burden, but also on evidence generation and payer acceptance. - The report’s regional outlook points to North America as the most mature commercial market, while other regions may develop more slowly as diagnostics and specialty care expand. - In October 2024, the National Asthma Council of Australia reported 474 asthma-related deaths in 2023, nearly matching 473 deaths in 2022. - The Association of the British Pharmaceutical Industry reported that industry-sponsored clinical trials in the UK rose from 411 in 2022 to 426 in 2023.

What's next: - The Business Research Company says future growth will track adoption of targeted biologics, progress in immunology research and broader use of early intervention strategies. - The company also highlighted new 2026 report features, including market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables. - Contact details for report inquiries include Saumya Sahay at marketing@tbrc.info and the phone numbers listed in the release.

The bottom line: - Tezspire is being positioned as a growing player in a larger biologics market driven by severe asthma, sharper diagnosis and stronger clinical research.